Literature DB >> 16618729

Identification of EZH2 as a molecular marker for a precancerous state in morphologically normal breast tissues.

Lei Ding1, Christine Erdmann, Arul M Chinnaiyan, Sofia D Merajver, Celina G Kleer.   

Abstract

The discovery of molecular markers to detect the precancerous state would have profound implications in the prevention of breast cancer. We report that the expression of the Polycomb group protein EZH2 increases in histologically normal breast epithelium with higher risk of developing cancer. We identify EZH2 as a potential marker for detecting preneoplastic lesions of the breast in vivo and as a possible target for preventative intervention.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16618729     DOI: 10.1158/0008-5472.CAN-05-4300

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  49 in total

Review 1.  Regulation of breast cancer metastasis signaling by miRNAs.

Authors:  Belinda J Petri; Carolyn M Klinge
Journal:  Cancer Metastasis Rev       Date:  2020-09       Impact factor: 9.264

Review 2.  Inhibitors of Protein Methyltransferases and Demethylases.

Authors:  H Ümit Kaniskan; Michael L Martini; Jian Jin
Journal:  Chem Rev       Date:  2017-03-24       Impact factor: 60.622

3.  Gene expression profiles of estrogen receptor-positive and estrogen receptor-negative breast cancers are detectable in histologically normal breast epithelium.

Authors:  Kelly Graham; Xijin Ge; Antonio de Las Morenas; Anusri Tripathi; Carol L Rosenberg
Journal:  Clin Cancer Res       Date:  2010-11-08       Impact factor: 12.531

4.  Increased risk for distant metastasis in patients with familial early-stage breast cancer and high EZH2 expression.

Authors:  Sharon Hensley Alford; Katherine Toy; Sofia D Merajver; Celina G Kleer
Journal:  Breast Cancer Res Treat       Date:  2011-05-26       Impact factor: 4.872

5.  Structure-Activity Relationship Studies for Enhancer of Zeste Homologue 2 (EZH2) and Enhancer of Zeste Homologue 1 (EZH1) Inhibitors.

Authors:  Xiaobao Yang; Fengling Li; Kyle D Konze; Jamel Meslamani; Anqi Ma; Peter J Brown; Ming-Ming Zhou; Cheryl H Arrowsmith; H Ümit Kaniskan; Masoud Vedadi; Jian Jin
Journal:  J Med Chem       Date:  2016-08-11       Impact factor: 7.446

6.  Potential epigenetic mechanism(s) associated with the persistence of psychoneurological symptoms in women receiving chemotherapy for breast cancer: a hypothesis.

Authors:  Debra Lyon; Lynne Elmore; Noran Aboalela; Jacqueline Merrill-Schools; Nancy McCain; Angela Starkweather; R K Elswick; Colleen Jackson-Cook
Journal:  Biol Res Nurs       Date:  2013-04-11       Impact factor: 2.522

7.  Dietary omega-3 polyunsaturated fatty acids suppress expression of EZH2 in breast cancer cells.

Authors:  Manjari Dimri; Prashant V Bommi; Anagh A Sahasrabuddhe; Janardan D Khandekar; Goberdhan P Dimri
Journal:  Carcinogenesis       Date:  2009-12-07       Impact factor: 4.944

8.  EZH2 inhibition decreases p38 signaling and suppresses breast cancer motility and metastasis.

Authors:  Heather M Moore; Maria E Gonzalez; Kathy A Toy; Ashley Cimino-Mathews; Pedram Argani; Celina G Kleer
Journal:  Breast Cancer Res Treat       Date:  2013-03-29       Impact factor: 4.872

9.  Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma.

Authors:  Nina Wagener; Stephan Macher-Goeppinger; Maria Pritsch; Johannes Hüsing; Karin Hoppe-Seyler; Peter Schirmacher; Jesco Pfitzenmaier; Axel Haferkamp; Felix Hoppe-Seyler; Markus Hohenfellner
Journal:  BMC Cancer       Date:  2010-10-04       Impact factor: 4.430

10.  Histone demethylase KDM6B promotes epithelial-mesenchymal transition.

Authors:  Sivakumar Ramadoss; Xiaohong Chen; Cun-Yu Wang
Journal:  J Biol Chem       Date:  2012-11-14       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.